Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo

Phytochemical profiling and antioxidant evaluation of Rhododendron arboreum Sm leaf and flower: integrative analysis using advanced analytical techniques

OBJECTIVE

This study investigates the biological activities of Rhododendron arboreum Sm from the eastern Himalayas, addressing a literature gap on its properties. It explores the plant's phytochemical, antioxidant, and medicinal characteristics.

SIGNIFICANCE

Evaluating methanolic extracts of R. arboreum offers valuable insights into its bioactive potential. Comprehensive GC-MS analysis identified a diverse array of compounds, highlighting the plant's chemical composition.

METHODS

Methanolic leaf and flower extracts underwent sequential extraction and phytochemical profiling using column chromatography, TLC, and GC-MS analysis. Spectral studies aided compound identification, and antioxidant activity was assessed via spectrophotometric assays.

RESULTS

Column chromatography separated methanol leaf and flower extracts into 17 and 24 distinct fractions, respectively. TLC analysis showed specific Rf values for leaf (0.58, 0.65, 0.75, 0.8, 0.86, 0.9) and flower samples (0.91, 0.38, 0.48, 0.51, 0.56, 0.6, 0.65, 0.75, 0.85, 0.96). GC-MS analysis revealed a variety of organic functional groups, including aliphatic hydrocarbons, aromatic compounds, heterocyclic molecules, phenolic compounds, steroids, terpenoids, alcohols, esters, and other bioactive compounds. FTIR spectra identified functional groups such as hydroxyls, primary amines, alkanes, and alkynes. NMR data indicated a complex molecular composition with diverse proton environments. Leaf extracts demonstrated superior antioxidant activity compared to flower extracts in DPPH, ABTS, hydrogen peroxide scavenging, lipid peroxidation inhibition, and FRAP assays.

CONCLUSION

The study identifies diverse phytochemicals in R.arboreum extracts and highlights their potential applications in pharmaceuticals, nutraceuticals, and functional foods, owing to the superior antioxidant activity of leaf extracts compared to flowers.

Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling

Colon cancer is the commonest cancer worldwide. α-Hederin is a monodesmosidic triterpenoid saponin possessing diverse pharmacological activities. The running experiment was designed to test the chemopreventive activity of α-hederin when used as an adjuvant to carboplatin in an experimental model of mouse colon hyperplasia induced by 1,2-dimethylhydrazine (DMH). Fifty male Swiss albino mice were classified into five groups: group (I): saline group, group (II): DMH-induced colon hyperplasia control group, group (III): DMH + carboplatin (5 mg/kg) group, group (IV): DMH + α-hederin (80 mg/kg) group, and group (V): DMH + carboplatin (5 mg/kg)+α-hederin (80 mg/kg) group. Analyzing of colonic tissue indicated that the disease control group showed higher colon levels of phospho-PI3K to total-PI3K, phospho-AKT to total-AKT and cyclin D1 concurrent with lower phospho-JNK/total JNK ratio and caspase 3. However, treatment with α-hederin, in combination with carboplatin, favorably ameliorated phosphorylation of PI3K/AKT/JNK proteins, increased colon caspase 3 and downregulated cyclin D1. Microscopically, α-hederin, in combination with carboplatin, produced the most reduction in the histologic hyperplasia score, enhanced the goblet cell survival in periodic acid Schiff staining and reduced proliferation (Ki-67 immunostaining) in the current colon hyperplasia model. Collectively, the current study highlighted for the first time that using α-hederin as an adjuvant to carboplatin enhanced its chemopreventive activity, improved JNK signaling and increased apoptosis. Hence, further studies are warranted to test α-hederin as a promising candidate with chemotherapeutic agents in treating colon cancer.

Regulatory T-cell density and cytotoxic T lymphocyte density are associated with complete response to neoadjuvant paclitaxel and carboplatin chemoradiotherapy in gastric cancer

Regulatory T-cell density and cytotoxic T lymphocyte density are crucial in regulating antitumor immune responses. Tumor infiltration has marked therapeutic effects in gastric carcinoma, and there is evidence that chemoradiotherapy (CRT) exhibits an immune-mediated component. In the present study, the density of CD4⁺ and CD8⁺ cells were evaluated in post-CRT surgical samples from 68 patients with gastric cancer using immunohistochemistry. The associations between T-cell density, cytotoxic T lymphocyte density and clinical survival rate were also analyzed. Cytotoxic T lymphocyte density was associated with gastric carcinoma regression grade and regulatory T-cell density was also associated with gastric carcinoma regression grade. Of the patients who had a pathologic complete response, 84 and 76% were found to have a high CD3⁺ and CD4⁺ cell density, which was significantly different to patients who had a low CD3⁺ and CD4⁺ cell density. High cytotoxic T lymphocyte density was also associated with improved survival rates of patients with gastric cancer. In conclusion, these outcomes indicated that regulatory T-cell density and cytotoxic T lymphocyte density in the tumor microenvironment were associated with the response to neoadjuvant CRT and may represent a therapeutic target for gastric cancer.

In vivo chemotherapeutic insight of a novel isocoumarin (3-hexyl-5,7-dimethoxy-isochromen-1-one): Genotoxicity, cell death induction, leukometry and phagocytic evaluation

Chemotherapy is one of the major approaches for the treatment of cancer. Therefore, the development of new chemotherapy drugs is an important aspect of medicinal chemistry. Chemotherapeutic agents include isocoumarins, which are privileged structures with potential antitumoral activity. Herein, a new 3-substituted isocoumarin was synthesized from 2-iodo-3,5-dimethoxy-benzoic acid and oct-1-yne in a cross-coupling Sonogashira reaction followed by a copper iodide-catalyzed intramolecular cyclization as key step using MeOH/Et₃N as the solvent system. The present study also evaluated the leukometry, phagocytic activity, genotoxic potential and cell death induction of three different doses (5 mg/kg, 10 mg/kg and 20 mg/kg) of this newly synthesized isocoumarin, alone and in combination with the commercial chemotherapeutic agents cyclophosphamide (100 mg/kg) and cisplatin (6 mg/kg) in male Swiss mice. The results suggest that the isocoumarin has genotoxicity and causes cell death. Noteworthy, this new compound can increase splenic phagocytosis and lymphocyte frequency, which are related to immunomodulatory activity. When combined with either cyclophosphamide or cisplatin, chemopreventive activity led to a reduction in the effects of both chemotherapeutic drugs. Thus, the new isocoumarin is not a candidate for chemotherapeutic adjuvant in treatments using cyclophosphamide or cisplatin. Nevertheless, the compound itself is an important prototype for the development of new antitumor drugs.

RNAi-mediated silencing of ezrin gene reverses malignant behavior of human gastric cancer cell line SGC-7901

OBJECTIVE

To investigate the effects of ezrin targeting gene of RNA interference (RNAi) on human gastric cancer cell line SGC-7901 in vitro.

METHODS

The highly metastatic human gastric cancer cell line SGC-7901 transfected with a small interfering (siRNA) lentivirus vector was selected for this research study. Expressions of ezrin mRNA and ezrin protein in the SGC-7901 cells were detected using RT-PCR and Western blot. Cell apoptosis was observed using flow cytometry. Transwell invasion and the cell adhesion test were used to verify the effect of RNAi on ezrin expression in the human gastric cancer cell line SGC-7901 in vitro.

RESULTS

Ezrin gene targeting via a RNAi-mediated lentivirus vector had obvious inhibitory effects on ezrin expression in the human gastric cancer cell line SGC-7901. The results of the RT-PCR show the obvious inhibition of ezrin mRNA expression in Eai and Ebi groups (0.22 +/- 0.01 vs 0.95 +/- 0.04, P < 0.05; 0.31 +/- 0.01 vs. 0.95 +/- 0.04, P < 0.05). Western blot analysis revealed a 72.35 +/- 3.74% reduction of the ezrin protein level after interference with the ezrin targeting gene. Moreover, the inhibition of ezrin expression clearly inhibited SGC-7901 cell migration and invasion, and improved cell adhesion as well as increased sensitivity to camptothecin-induced apoptosis.

CONCLUSION

Ezrin gene targeting by RNAi can inhibit the metastatic growth and migration of SGC-7901 human gastric cancer cells.